Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO study.

Authors

Tunde Peto, Ian Pearce, James Talks, Gabriella de Salvo, Praveen J Patel, Samantha R de Silva, Richard P Gale, Sobha Sivaprasad, Deepali Varma, Rhianon Reynolds, Clare Bailey, Louise Downey, Christine Kiire, Gloria C Chi, Melanie Dodds, Natalee James, Amanda K Downey, Parul Dayal

Published in

Eye (London, England). Oct 23, 2025. Epub Oct 23, 2025.

Abstract

The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with diabetic macular oedema (DMO)/neovascular age-related macular degeneration (nAMD) treated with faricimab in the UK. We present results from FARWIDE-DMO for eyes with 12 months of follow-up after faricimab initiation.
FARWIDE-DMO includes patients with diagnosis of DMO who received ≥1 intravitreal faricimab injection after May 2022 in the diagnosed eye(s) at 1 of 35 UK National Health Service sites. All eyes had ≥12 months of follow-up after faricimab initiation as of July 2024. Treatment-naïve (TN) eyes had no prior anti-VEGF therapy or steroid implant. Previously treated (PT) eyes switched to faricimab. Baseline characteristics, visual acuity (VA) outcomes and treatment patterns were evaluated. Intraocular inflammation (IOI) and presumed infectious endophthalmitis (PIE) incidences were pooled for all nAMD/DMO eyes with any follow-up duration. Analyses are descriptive.
2147 eyes (1564 patients) were included (TN, 32.1%; PT, 67.9%). For TN eyes, mean (standard deviation [SD]) VA at baseline and 12 months were 63.9 (15.2) and 68.4 (16.3) Early Treatment Diabetic Retinopathy Study letters, respectively. VA remained stable in PT eyes. TN eyes received a mean (SD) of 4.5 (1.0) faricimab injections in months 1-6 and 1.9 (1.2) injections in months 7-12. PT eyes received 4.5 (1.2) injections in months 1-6 and 2.4 (1.3) in months 7-12. IOI and PIE rates were consistent with faricimab phase 3 trials.
These 1-year data support real-world effectiveness, durability and safety of faricimab in DMO.

PMID:
41131329
Bibliographic data and abstract were imported from PubMed on 24 Oct 2025.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.